Bionomics Limited

ABN 53 075 582 740

**ASX ANNOUNCEMENT**
**15 August 2012**

# Bionomics secures key US patent for vascular disrupting agent BNC105

- **Cancer drug candidate BNC105 in Phase I/II & Phase II clinical trials for ovarian and kidney cancer**
- **In 2010 there were an estimated 21,880 new cases & 13,850 deaths from ovarian cancer in the US. $2.2b pa is spent in the US treating ovarian cancer**
- **Over 100,000 people die of kidney cancer in the world each year**

**15 August 2012:** Bionomics Limited (ASX: BNO, ADR: BMICY) has been granted its key patent (US 8,198,466) relating to its vascular disrupting agent BNC105 by the United States Patent and Trademark Office. This patent is at the centre of the BNC105 patent portfolio.

The patent is valid for 20 years to February 2027. BNC105 patents have been filed in each of the major pharmaceutical markets. Granting of this patent has already occurred in Australia and New Zealand.

BNC105 recently entered a phase I/II trial in ovarian cancer across sites in Australia, New Zealand and the United States following strong preclinical data showing synergy with platinum-based agents. BNC105 is being evaluated in combination with carboplatin and gemcitabine.

BNC105 is also undergoing evaluation in a phase II US multicentre trial in combination with mTOR inhibitor (Afinitor) in metastatic renal cell carcinoma, a form of kidney cancer.

CEO and Managing Director of Bionomics Dr Deborah Rathjen said the granting of this patent in the US is a milestone in Bionomics' patent strategy for the BNC105 program.

"This solidifies our intellectual property protection for Bionomics' lead oncology clinical stage asset. The granted patent provides a substantial value-add for the BNC105 program and strengthens our partnering data package."

Bionomics has also filed a patent application for the manufacture of BNC105.

Bionomics owns additional patents and has applications covering vascular disrupting agents related to BNC105, together with methods of treatment of cancer both as monotherapy and in combination with selected therapies.

**Enquiries:**


**Bionomics Limited**
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101/
0418 160 425
drathjen@bionomics.com.au

**Monsoon Communications**
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

**The Trout Group**
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com


**About Bionomics Limited**
Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, Alzheimer's disease, epilepsy and multiple sclerosis.BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.
www.bionomics.com.au

***Factors Affecting Future Performance***
*This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of either BNC105 or BNC210, our partnership Ironwood Pharmaceuticals, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.*